Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-up - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Clinics and Research in Hepatology and Gastroenterology Année : 2022

Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-up

Résumé

Not available.
Fichier non déposé

Dates et versions

hal-04039623 , version 1 (21-03-2023)

Identifiants

Citer

Zelika Harouna Hamidou, Madjid Morsli, Saidou Mamadou, Michel Drancourt, Jamal Saad. Bulevirtide 2mg-based real-life treatment of hepatitis Delta with genotypes 1 and 5 viruses at more than 20 months of follow-up. Clinics and Research in Hepatology and Gastroenterology, 2022, 46 (10), pp.102035. ⟨10.1016/j.clinre.2022.102035⟩. ⟨hal-04039623⟩

Collections

CNRS UNIV-AMU
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More